

DAFTAR PUSTAKA

- Aini N, Kasno, Basuki R, 2015. Hubungan Antara Ekspresi Protein Her-2/Neudengan Derajat Diferensiasi Penderita Karsinoma Payudara Jenis Duktus Invasif. *Jurnal Kedokteran Muhammadiyah*, Vol. 2, No. 1, pp 12-5.
- Ali Y and Hamid SA, 2016. Human Topoisomerase II Alpha as A Prognostic Biomarker in Cancer Chemotherapy. *Tumour Biol*, Vol. 37, No. 1, pp. 47-55.
- Al-Janabi S, van Slooten HJ, Visser M, van der Ploeg T, van Diest PJ, Jiwa M, 2013. Evaluation of Mitotic Activity Index in Breast Cancer Using Whole Slide Digital Images. *PLoS ONE*, Vol. 8, No. 12, pp. 1-9.
- Allemani C, Weir HK, Carreira H *et al.*, 2015. Global Surveillance of Cancer Survival 1995-2009: Analysis of Individual Data for 25.676.887 Patients from 279 Population-based Registries in 67 Countries (CONCORD-2). *Lancet*, Vol. 385, No. 9972, pp. 1-34.
- Allison KH, 2012. Molecular Pathology of Breast Cancer. What A Pathologist Needs to Know. *Am J Clin Pathol*, Vol. 138, No. 6, pp. 770-80.
- Allred C, Miller K, Viale G, Brogi E, Isola J, 2012. Molecular Testing for Estrogen Receptor, Progesterone Receptor and HER2. In (Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, eds) *WHO Classification of Tumours of The Breast*, 4th ed. Lyon: International Agency for Research on Cancer, pp. 22-3.
- Almeida D, Gerhard R, Leitão D, Davilla C, Damasceno M, Schmitt F, 2014. Topoisomeras II-Alfa Gene as A Predictive Marker of Response to Anthracyclines in Breast Cancer. *Pathology-Research and Practice*, pp. 675-79.
- American Cancer Society, 2015. *Cancer Facts and Figures 2015*. Atlanta: American Cancer Society Inc, pp. 9-11.
- American Cancer Society, 2017. *Breast Cancer Facts & Figures 2017-2018*. Atlanta: American Cancer Society, Inc, pp. 1-44.
- An X, Xu F, Luo R *et al.*, 2018. The Prognostic Significance of Topoisomerase II Alpha Protein in Early Stage Luminal Breast Cancer. *BMC Cancer*, Vol. 18, No. 331, pp. 1-10.
- Angahar LT, 2017. An Overview of Breast Cancer Epidemiology, Risk Factors, Pathophysiology and Cancer Risks Reduction. *MedCrave Online Journal of Biology and Medicine*, Vol. 1, No. 4, pp. 1-5.

- Arciero CA and Styblo TM, 2018. Clinically Established Prognostic Factors in Breast Cancer. In (Bland KI, Copeland EM, Klimberg VS, Gradishar WJ, eds) *The Breast: Comprehensive Management of Benign and Malignant Diseases*, 5th ed. Philadelphia: Elsevier, pp. 250-7.
- Aryandono T, Harijadi, Soeripto, 2006. Hormone Receptor Status of Operable Breast Cancers in Indonesia: Correlation with Other Prognostic Factors and Survival. *Asian Pac J Cancer Prev*, Vol. 7, No. 2, pp. 321-4.
- Ataseven B, Gologan D, Gunesch A *et al.*, 2012. HER2/neu, Topoisomerase 2 α , Estrogen and Progesterone Receptors: Discordance Between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics. *Breast Care*, Vol. 7, No. 6, pp. 465-70.
- Baak JPA, Gudlaugsson E, Skaland I *et al.*, 2009. Proliferation is The Strongest Prognosticator in Node-Negative Breast Cancer: Significance, Error Sources, Alternatives and Comparison with Molecular Prognostic Markers. *Breast Cancer Res Treat*, Vol. 115, No.2, pp. 241-54.
- Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Indonesia, 2018. *Kanker di Indonesia Tahun 2014: Data Histopatologik*. Jakarta: Yayasan Kanker Indonesia.
- Baker AT, Zlobin A, Osipo C, 2014. Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer. *Front Oncol*, Vol. 4, No. 360, pp. 1-15.
- Bavle RM, 2014. Enigmatic Morpho Insight: Mitosis at A Glance. *J Oral Maxillofac Pathol*, Vol. 18, Suppl 1, pp. S2-5.
- Biesaga B, Niemiec J, Ziobro M, 2014. BCL-2, Topoisomerase II α , Microvessel Density and Prognosis of Early Advanced Breast Cancer Patients After Adjuvant Anthracycline-based Chemotherapy. *J Cancer Res Clin Oncol*, Vol. 140, No. 12, pp. 2009-19.
- Bonert M, Tate AJ, 2017. Mitotic Counts in Breast Cancer Should be Standardized with A Uniform Sample Area. *BioMed Eng OnLine*, Vol 16, No. 1, pp. 1-8.
- Chen JR, Chien HP, Chen KS *et al.*, 2017. Amplification of HER2 and TOP2A and Deletion of TOP2A Genes in A Series of Taiwanese Breast Cancer. *Medicine*, Vol. 96, No. 2, pp. 1-9.
- Chen T, Sun Y, Ji P, Kopetz S, Zhang W, 2015. Topoisomerase II α in Chromosome Instability and Personalized Cancer Therapy. *Oncogene*, Vol. 34, No. 31, pp. 4019-31.
- Coates AS, Winer EP, Goldhirsch A *et al.*, 2015. Tailoring Therapies-Improving The Management of Early Breast Cancer: St Gallen International Expert

Consensus on The Primary Therapy of Early Breast Cancer 2015. *Ann Oncol*, Vol. 26, No. 8, pp. 1533-46.

Colditz G, Chia KS, 2012. Epidemiology Invasive Breast Carcinoma. In (Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, eds) *WHO Classification of Tumours of The Breast*, 4th ed. Lyon: International Agency for Research on Cancer, pp. 14-7.

Curado MP, 2011. Breast Cancer in The World: Incidence and Mortality. *Salud Publica Mex*, Vol. 53, No. 5, pp. 372-84.

Dai X, Xiang L, Li T, Bai Z, 2016. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. *J Cancer*, Vol. 7, No. 10, pp. 1281-94.

Denduluri SK, Idowu O, Wang Z *et al.*, 2015. Insulin-like Growth Factor (IGF) Signaling in Tumorigenesis and The Development of Cancer Drug Resistance. *Genes Dis*, Vol. 2, No. 1, pp. 13-25.

Devi CRB, Tang TS, Corbex M, 2012. Incidence and Risk Factors for Breast Cancer Subtypes in Three Distinct South-East Asian Ethnic Groups: Chinese, Malay and Natives of Sarawak, Malaysia. *Int J Cancer*, Vol. 131, No. 12, pp. 2869-77.

Dey N, Leyland-Jones B, De P, 2016. HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies. In (Dey N, De P, Leyland-Jones B, eds) *PI3K-mTOR in Cancer and Cancer Therapy*. New York: Springer Science+Business Media, pp. 231-61.

Dittrich A, Gautrey H, Browell D, Tyson-Capper A, 2014. The HER2 Signaling Network in Breast Cancer-like A Spider in Its Web. *J Mammary Gland Biol Neoplasia*, Vol. 19, No. 3-4, pp. 253-70. DOI 10.1007/s10911-014-9329-5.

Duru N, Candas D, Jiang G, Li JJ, 2014. Breast Cancer Adaptive Resistance: HER2 and Cancer Stem Cell Repopulation in A Heterogeneous Tumor Society. *J Cancer Res Clin Oncol*, Vol. 140, No.1, pp. 1-14.

Dwina Y, Kodariah R, Hardjolukito ESR, 2014. Identification of Pathogenesis Pathway in Basal-like Breast Cancer Based on Mutant p53 Protein and Topoisomerase-II α Expression. *Med J Indones*, Vol. 23, No. 4, pp. 197-202.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2012. Comparisons Between Different Polychemotherapy Regimens for Early Breast Cancer: Meta-analyses of Long-term Outcome Among 100.000 Women in 123 Randomised Trials. *Lancet*, Vol. 379, No. 9814, pp. 432-44.

- Ellis IO, Collins L, Ichihara S, MacGrogan G, 2012. Invasive Carcinoma of No Special Type. In (Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, eds) *WHO Classification of Tumours of The Breast*, 4th ed. Lyon: International Agency for Research on Cancer, pp. 34-8.
- Ellis IO, Simpson JS, Reis-Filho JS, Decker T, 2012. Grading Invasive Breast Carcinoma. In (Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, eds) *WHO Classification of Tumours of The Breast*, 4th ed. Lyon: International Agency for Research on Cancer, pp. 19-20.
- Fan L, Goss PE, Strasser-Weippl K, 2015. Current Status and Future Projections of Breast Cancer in Asia. *Breast Care (Basel)*, Vol. 10, No. 6, pp. 372-8.
- Fayanju OM and Lucci A, 2018. Molecular Prognostic Factors for Breast Carcinoma. In (Bland KI, Copeland EM, Klimberg VS, Gradishar WJ, eds) *The Breast: Comprehensive Management of Benign and Malignant Diseases*, 5th ed. Philadelphia: Elsevier, pp. 258-63.
- Ferlay J, Héry C, Autier P, Sankaranarayanan R, 2010. Global Burden of Breast Cancer. In (Li CI, ed) *Breast Cancer Epidemiology*. New York: Springer Science+Business Media, pp. 1-19.
- Ferlay J, Soerjomataram I, Dikshit R *et al.*, 2015. Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. *Int J Cancer*, Vol. 136, No. 5, pp. 359-86.
- Forterre P, 2012. Introduction and Historical Perspective. In (Pommier Y, ed) *DNA Topoisomerases and Cancer*. New York: Springer Science+Business Media, pp. 1-52.
- Fountzilas G, Valavanis C, Kotoula V, 2012. HER2 and TOP2A in High-risk Early Breast Cancer Patients Treated with Adjuvant Epirubicin-based Dose-dense Sequential Chemotherapy. *J Transl Med*, Vol. 10, No. 10, pp. 1-21.
- Fountzilas G, Dafni U, Bobos M *et al.*, 2013. Evaluation of The Prognostic Role of Centromere 17Gain and HER2/Topoisomerase II Alpha Gene Status and Protein Expression in Patients with Breast Cancer Treated with Anthracycline-containing Adjuvant Chemotherapy: Pooled Analysis of Two Hellenic Cooperative Oncology Group (HeCOG) Phase III Trials. *BMC Cancer*, Vol. 13, No. 163, pp. 1-16.
- Gajria D, Chandarlapaty S, 2011. HER2-amplified Breast Cancer: Mechanisms of Trastuzumab Resistance and Novel Targeted Therapies. *Expert Rev Anticancer Ther*. Vol. 11, No. 2, pp. 263-75.
- Garnier F, Debat H, Nadal M, 2018. Type IA DNA Topoisomerases: A Universal Core and Multiple Activities. In (Drolet M, ed) *DNA Topoisomerases*:

Methods and Protocols. New York: Springer Science+Business Media, pp. 1-20.

Ghoncheh M, Pournamdar Z, Salehiniya H, 2016. Incidence and Mortality and Epidemiology of Breast Cancer in The World. *Asian Pac J Cancer Prev, Cancer Control in Western Asia Special Issue*, Vol. 17, S3, pp. 43-6.

Gnant M, Harbeck N, Thomssen C, 2017. St. Gallen/Vienna 2017: A Brief Summary of The Consensus Discussion About Escalation and De-escalation of Primary Breast Cancer Treatment. *Breast Care*, Vol. 12, No. 2, pp. 102-7.

Goldhirsch A, Winer EP, Coates AS *et al.*, 2013. Personalizing The Treatment of Women with Early Breast Cancer: Highlights of The St Gallen International Expert Consensus on The Primary Therapy of Early Breast Cancer 2013. *Ann of Oncol*, Vol. 24, No. 9, pp. 2206-23.

Gradishar WJ, Anderson BO, Balassanian R *et al.*, 2017. NCCN Guidelines® Insights Breast Cancer, Version 1.2017. *J Natl Compr Canc Netw*, Vol. 15, No. 4, pp. 433-51.

Gruver AM, Portier BP, Tubbs RR, 2011. Molecular Pathology of Breast Cancer. The Journey from Traditional Practice Toward Embracing The Complexity of A Molecular Classification. *Arch Pathol Lab Med*, Vol. 135, No. 5, pp. 544-57.

Hammond MEH, Hayes DF, Dowsett M *et al.*, 2010. American Society of Clinical Oncology/College of AmericanPathologists Guideline Recommendations forImmunohistochemical Testing of Estrogen and ProgesteroneReceptors in Breast Cancer. *Archives of Pathology and Laboratory Medicine*, Vol. 134, No. 6, pp. 907-22.

Harahap WA, 2014. Metilasi Promoter Breast Cancer Gene 1 dan Hubungannya dengan Faktor Prognostik Karsinoma Payudara Sporadik Premenopause pada Etnis Minang. *Disertasi*, Universitas Andalas, Indonesia.

Heestand GM, Schwaederle M, Gatalica Z, Arguello D, Kurzrock R, 2017. Topoisomerase Expression and Amplification in Solid Tumours: Analysis of 24,262 Patients. *Eur J Cancer*, Vol. 83, pp. 80-7.

Hein SM, Haricharan S, Johnston AN *et al.*, 2016. Luminal Epithelial Cells Within The Mammary Gland Can Produce Basal Cells upon Oncogenic Stress. *Oncogene*, Vol. 35, No. 11, pp. 1461-7.

Hoda SA, 2014. Invasive Ductal Carcinoma: Assessment of Prognosis with Morphologic and Biologic Markers. In (Hoda SA, Brogi E, Koerner FC, Rosen PP, eds) *Rosen's Breast Pathology*, 4th ed. Philadelphia: Wolters Kluwer, pp. 413-67.

- Hoda SA, 2014. Precarcinomatous Breast Disease: Epidemiologic, Pathologic and Clinical Considerations. In (Hoda SA, Brogi E, Koerner FC, Rosen PP, eds) *Rosen's Breast Pathology*, 4th ed. Philadelphia: Wolters Kluwer, pp. 309-30.
- Hoda SA, Resetkova E, 2014. Pathologic Examination of Breast and Lymph Node Specimens, Including Sentinel Lymph Nodes. In (Hoda SA, Brogi E, Koerner FC, Rosen PP, eds) *Rosen's Breast Pathology*, 4th ed. Philadelphia: Wolters Kluwer, pp. 1263-5.
- Humphries MP, Jordan VC, Speirs V, 2015. Obesity and Male Breast Cancer: Provocative Parallels?. *BMC Medicine*, Vol. 13, No. 134, pp. 1-9.
- Hutagalung SB, Mulyadi IK, Artha IGA, 2014. Ekspresi Ki-67 dan HER-2/neu Berhubungan dengan Derajat Histopatologik Karsinoma Payudara Invasif *No Special Type* (NST). *Majalah Patologi Indonesia*, Vol. 23, No. 2, pp. 45-50.
- Ignatov T, Eggemann H, Burger E, Fettke F, Costa SD, Ignatov A, 2015. Moderate Level of HER2 Expression and Its Prognostic Significance in Breast Cancer with Intermediate Grade. *Breast Cancer Res Treat*, Vol. 151, No. 1, pp. 357-64.
- Islam RM, Billah B, Hossain MN, Oldroyd J, 2017. Barriers to Cervical Cancer and Breast Cancer Screening Uptake in Low-Income and Middle-Income Countries: A Systematic Review. *Asian Pac J Cancer Prev*, Vol. 18, No. 7, pp. 1751-63.
- Iqbal N, Iqbal N, 2014. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. *Molecular Biology International*. Hindawi Publishing Corporation, 852748, pp. 1-9. <http://dx.doi.org/10.1155/2014/852748>, diakses pada tanggal 20 Oktober 2017.
- Iyikesici MS, Basaran G, Dane F *et al.*, 2014. Associations Between Clinicopathological Prognostic Factors and pAkt, pMAPK and Topoisomerase II Expression in Breast Cancer. *Int J Clin Exp Med*, Vol. 7, No. 5, pp. 1459-64.
- Jatiluhur IM, Yantisetiasti A, Hassan AH, Hernowo BS, 2014. Hubungan antara HER-2/neu dan Ki-67 dengan Respon Kemoterapi Neoadjuvan pada Karsinoma Payudara Lanjut Lokal. *Majalah Patologi Indonesia*, Vol. 23, No. 3, pp. 32-40.
- Kadi TA, Hoesin F, 2014. Ekspresi *Matrix Metalloproteinase-9* (MMP-9), HER-2/neu dan Metastasis Kelenjar Getah Bening pada Karsinoma Payudara Duktal Invasif. *Majalah Patologi Indonesia*, Vol. 23, No. 1, pp. 28-34.

- Kamarlis RK, 2017. Analisa Korelasi *SOX2* dan *p63* dalam Penentuan Gambaran Histopatologik Kanker Payudara Jenis *Basal-like* dan *NonBasal-like*. *Disertasi*, Universitas Sumatera Utara, Indonesia.
- Karlsson E, 2014. Prognosis and Predictive Factors in Human Breast Cancer During Tumor Progression. *Thesis*, Karolinska Institutet, Swedia.
- Kementerian Kesehatan RI, 2016. Kanker Payudara. Pusat Data dan Informasi Kementerian Kesehatan RI (Info Datin), pp. 1-11. Available from: <http://www.depkes.go.id/folder/view/01/structure-publikasi-pusdatin-info-datin.html>, diakses pada tanggal 29 Mei 2018.
- Khambri D, 2015. Hubungan Ekspresi *Androgen Receptor* dengan Faktor Prognostik Karsinoma Payudara di Sumatera Barat. *Disertasi*, Universitas Andalas, Indonesia.
- Korourian S, Kumarapeli AR, Klimberg VS, 2018. Breast Biomarker Immunocytochemistry. In (Bland KI, Copeland EM, Klimberg VS, Gradishar WJ, eds) *The Breast: Comprehensive Management of Benign and Malignant Diseases*, 5th ed. Philadelphia: Elsevier, pp. 197-206.
- Kosasih J, Artha IGA, 2011. Hubungan Overekspresi Topoisomerase II Alfa dengan Overekspresi Her-2/neu dan Berbagai Derajat Histologik Karsinoma Duktal Invasif Tidak Spesifik Payudara. *Majalah Patologi Indonesia*, Vol. 20, No. 1, pp. 6-13.
- Kumar V, Abbas AK, Aster JC, 2015. Neoplasia. In (Kumar V, Abbas AK, Aster JC, eds) *Robbins and Cotran Pathologic Basis of Disease*, 9th ed. Philadelphia: Elsevier Saunders, pp. 321-4.
- Lee LH, Yang H, Bigras G, 2014. Current Breast Cancer Proliferative Markers Correlate Variably Based on Decoupled Duration of Cell Cycle Phases. *Scientific Reports*, Vol. 4, No. 5122, pp. 1-8.
- Lester SC, 2015. The Breast. In (Kumar V, Abbas AK, Aster JC, eds) *Robbins and Cotran Pathologic Basis of Disease*, 9th ed. Philadelphia: Elsevier Saunders, pp. 1051-64.
- Lin F, Shi J, 2015. Standardization of Diagnostic Immunohistochemistry. In (Lin F, Prichard J, eds) *Handbook of Practical Immunohistochemistry, Frequently Asked Questions*, 2nd ed. New York: Springer Science+Business Media, pp. 17-30.
- Li XY, Li M, Jin F, 2016. Topoisomerase II α and BRCA1 Expression as Predictive Factors for Anthracycline-based Adjuvant Chemotherapy Response and Prognosis in Triple-negative Breast Cancers. *Int J Clin Exp Pathol*, Vol. 9, No. 9, pp. 9249-58.

- Li X, Oprea-Ilie GM, Krishnamurti U, 2017. New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. *Archives of Pathology and Laboratory Medicine*, Vol. 141, No. 4, pp. 490-8.
- Ly A, Lester SC, Dillon D, 2012. Prognostic Factors for Patients with Breast Cancer: Traditional and New. *Surgical Pathology*, Vol. 5, No.3, pp. 775-85.
- Makki J, 2015. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. *Clinical Medicine Insights: Pathology*, Vol. 8, pp. 23-31.
- Martin HL, Smith L, Tomlinson DC, 2014. Multidrug-resistant Breast Cancer: Current Perspectives. *Breast Cancer: Targets and Therapy*, Vol. 6, pp. 1-13.
- Masoud V, Pages G, 2017. Targeted Therapies in Breast Cancer: New Challenges to Fight Against Resistance. *World J Clin Oncol*, Vol. 8, No. 2, pp. 120-34.
- Matsumoto A, Jinno H, Ando T *et al.*, 2016. Biological Markers of Invasive Breast Cancer. *Jpn J Clin Oncol*, Vol. 46, No. 2, pp. 99-105.
- Meuten DJ, Moore FM, George JW, 2016. Mitotic Count and The Field of View Area: Time to Standardize. *Veterinary Pathology*, Vol. 53, No. 1, pp. 7-9.
- Mitchell RN, 2015. The Cell as A Unit of Health and Disease. In (Kumar V, Abbas AK, Aster JC, eds) *Robbins and Cotran Pathologic Basis of Disease*, 9th ed. Philadelphia: Elsevier Saunders, pp. 1-29.
- Mohan H, 2015. *Textbook of Pathology*, 7th ed. New Delhi: Jaypee Brothers Medical Publishers, pp. 745-58.
- Moinfar F, 2007. *Essentials of Diagnostic Breast Pathology, A Practical Approach*. New York: Springer-Verlag, pp. 2-5.
- Mook S, 2011. Prognostic Factors in Breast Cancer. One Fits All?. *Thesis*, University of Amsterdam, Netherlands.
- Morrow M, Rutgers E, 2012. Clinical Features Invasive Breast Carcinoma. In (Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, eds) *WHO Classification of Tumours of The Breast*, 4th ed. Lyon: International Agency for Research on Cancer, pp. 18-9.
- Mousavi SM, Mohagheghi MA, Mousavi-Jerrahi A, Nahvijou A, Seddighi Z, 2006. Burden of Breast Cancer in Iran: A Study of The Tehran Population Based Cancer Registry. *Asian Pac J Cancer Prev*, Vol. 7, No.4, pp. 571-4.

- Muhartono, Ramanisa R, Mutiara H, Riduan RJ, 2016. Hubungan antara Status Reseptor Estrogen, Reseptor Progesteron dan Human Epidermal Growth Factor Receptor 2 dengan Derajat Keganasan Karsinoma Payudara Invasif. *Majalah Kedokteran Andalas*, Vol. 39, No. 2, pp. 65-72.
- Mukherjee A, Shehata M, Moseley P, Rakha E, Ellis I, Chan S, 2010. Topo2a Protein Expression Predicts Response to Anthracycline Combination Neo-adjuvant Chemotherapy in Locally Advanced Primary Breast Cancer. *Br J Cancer*, Vol. 103, No. 12, pp. 1794-800.
- Mulligan AM, O'Malley FP, 2015. The Breast. In (Strayer DS, Rubin E, Saffitz JE, Schiller AL, eds) *Rubin's Pathology Clinicopathologic Foundations of Medicine*, 7th ed. Philadelphia: Wolters Kluwer, pp. 1064-78.
- Nelson H, Maulani H, Farida A, Saleh MI, 2014. Hubungan antara Ekspresi *Vascular Endothelial Growth Factor* (VEGF) dengan Karakteristik Klinikopatologik Karsinoma Payudara Duktal Invasif. *Majalah Patologi Indonesia*, Vol. 23, No. 1, pp. 48-53.
- Neubauer E, Wirtz RM, Kaemmerer D *et al.*, 2016. Comparative Evaluation of Three Proliferation Markers, Ki-67, TOP2A and RacGAP1, in Bronchopulmonary Neuroendocrine Neoplasms: Issues and Prospects. *Oncotarget*, Vol. 7, No. 27, pp. 41959-73.
- Neumayer L, Viscusi RK, 2018. Assessment and Designation of Breast Cancer Stage. In (Bland KI, Copeland EM, Klimberg VS, Gradishar WJ, eds) *The Breast: Comprehensive Management of Benign and Malignant Diseases*, 5th ed. Philadelphia: Elsevier, pp. 531-5.
- Nikolényi A, Uhercsák G, Csenki M *et al.*, 2012. Tumour Topoisomerase II Alpha Protein Expression and Outcome After Adjuvant Dose-dense Anthracycline-based Chemotherapy. *Pathol. Oncol. Res*, Vol. 18, No. 1, pp. 61-8.
- Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N, 2010. Ki-67 as A Prognostic Marker According to Breast Cancer Subtype and A Predictor of Recurrence Time in Primary Breast Cancer. *Exp Ther Med*, Vol. 1, No. 5, pp. 747-54.
- Ng CH, Pathy NB, Taib NA *et al.*, 2011. Comparison of Breast Cancer in Indonesia and Malaysia-A Clinicopathological Study Between Dharmas Cancer Centre Jakarta and University Malaya Medical Centre, Kuala Lumpur. *Asian Pac J Cancer Prev*, Vol. 12, No. 11, pp. 2943-6.
- Norum JH, Andersen K, Sørli T, 2014. Lessons Learned from The Intrinsic Subtypes of Breast Cancer in The Quest for Precision Therapy. *Br J Surg*, Vol. 101, No. 8, pp. 925-38.

- Ossovskaya V, Wang Y, Budoff A *et al.*, 2011. Exploring Molecular Pathways of Triple-negative Breast Cancer. *Genes & Cancer*, Vol. 2, No. 9, pp. 870-9.
- Pareja F, Pines G, Yarden Y, 2015. The EGFR/ERBB Receptor Family. In (Wheeler DL, Yarden Y, eds) *Receptor Tyrosine Kinases: Family and Subfamilies*. Switzerland: Springer International Publishing, pp. 107-64.
- Parise CA, Caggiano V, 2014. Breast Cancer Survival Defined by The ER/PR/HER2 Subtypes and A Surrogate Classification According to Tumor Grade and Immunohistochemical Biomarkers. *J Cancer Epidemiol*, Hindawi Publishing Corporation, Article ID 469251, pp. 1-11.
- Payandeh M, Shahriari-Ahmadi A, Sadeghi M, Sadeghi E, 2016. Correlations Between HER-2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with The Ki-67 Index and P53 Status. *Asian Pac J Cancer Prev*, Vol. 17, No. 3, pp. 1015-18.
- Perou CM, Sorlie T, Eisen MB *et al.*, 2000. Molecular Portraits of Human Breast Tumours. *Nature*, Vol. 406, No. 6797, pp. 747-52.
- Pinder SE, Lee AHS, Ellis IO, 2014. The Breasts. In (Herrington CS, ed) *Muir's Textbook of Pathology*, 15th ed. Boca Raton: Taylor and Francis Group, pp. 451-60.
- Pommier Y, 2013. Drugging Topoisomerases: Lessons and Challenges. *ACS Chem Biol*, Vol. 8, No. 1, pp. 82-95.
- Prichard J, 2015. Immunohistochemistry Quality Management and Regulation. In (Lin F, Prichard J, eds) *Handbook of Practical Immunohistochemistry, Frequently Asked Questions*, 2nd ed. New York: Springer Science + Business Media, pp. 1-16.
- Qiao JH, Jiao DC, Lu ZD, Yang S, Liu ZZ, 2015. Clinical Significance of Topoisomerase 2A Expression and Gene Change in Operable Invasive Breast Cancer. *Tumour Biol*, Vol. 36, No. 9, pp. 1-6.
- Rahman A, Sampepajung D, Hamdani W, 2014. Correlation Between HER-2/neu and Hormonal Receptor with Histopathology Grading on Young Women Breast Cancer, pp. 1-12. Available from: <http://pasca.unhas.ac.id/jurnal/> diakses pada tanggal 29 Mei 2018.
- Ren L, Liu J, Gou K, Xing C, 2018. Copy Number Variation and High Expression of DNA Topoisomerase II Alpha Predict Worse Prognosis of Cancer: A Meta-analysis. *J Cancer*, Vol. 9, No. 12, pp. 2082-92.

- Romero A, Caldes T, Díaz-Rubio E, Martín M, 2012. Topoisomerase 2 Alpha: A Real Predictor of Anthracycline Efficacy?. *Clin Transl Oncol*, Vol. 14, No. 3, pp. 163-8.
- Romero A, Martin M, Cheang MC *et al.*, 2011. Assessment of Topoisomerase II Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization. *Am J Pathol*, Vol. 178, No. 4, pp. 1453-60.
- Rosa M, 2015. Advances in The Molecular Analysis of Breast Cancer: Pathway Toward Personalized Medicine. *Cancer Control*, Vol. 22, No. 2, pp. 211-9.
- Roux L, Racoreanu D, Loménié N *et al.*, 2013. Mitosis Detection in Breast Cancer Histological Images An ICPR 2012 Contest. *J Pathol Inform*, Vol. 4, No. 8, pp.1-7.
- Russell CA, 2014. Personalized Medicine for Breast Cancer: It is A New Day!. *Am J Surg*, Vol. 207, No. 3, pp. 321-5.
- Sakhdari A, Hutchinson L, Cosar EF, 2015. Molecular Pathology of HER Family of Oncogenes in Breast Cancer: HER-2 Evaluation and Role in Targeted Therapy. In (Khan A, Ellis IO, Hanby AM, Cosar EF, Rakha EA, Kandil D, eds) *Precision Molecular Pathology of Breast Cancer*. New York: Springer Science+Business Media, pp. 119-36.
- Sanguinetti A, Polistena A, Lucchini R *et al.*, 2016. Male Breast Cancer, Clinical Presentation, Diagnosis and Treatment: Twenty Years of Experience in Our Breast Unit. *Int J Surg Case Rep*, Vol. 20, Suppl, pp. 8-11.
- Santa-Maria CA, Gradishar WJ, 2018. Adjuvant and Neoadjuvant Systemic Therapies for Early-Stage Breast Cancer. In (Bland KI, Copeland EM, Klimberg VS, Gradishar WJ, eds) *The Breast: Comprehensive Management of Benign and Malignant Diseases*, 5th ed. Philadelphia: Elsevier, pp. 752-62.
- Schindlbeck C, Mayr D, Olivier C *et al.*, 2010. Topoisomerase II Expression Rather than Gene Amplification Predicts Responsiveness of Adjuvant Anthracycline-based Chemotherapy in Women with Primary Breast Cancer. *J Cancer Res Clin Oncol*, Vol. 136, No. 7, pp. 1029-37.
- Schaefer-Klein JL, Murphy SJ, Johnson SH, Vasmataz G, Kovtun IV *et al.*, 2015. Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression. *PloS ONE*, Vol. 10, No. 11, pp. 1-17. doi:10.1371/journal.pone.0142327.

- Shigematsu H, Ozaki S, Yasui D *et al.*, 2018. Overexpression of Topoisomerase II Alpha Protein is A Factor for Poor Prognosis in Patients with Luminal B Breast Cancer. *Oncotarget*, Vol. 9, No. 42, pp. 26701-10.
- Shokouh TZ, Ezatollah A, Barrand P, 2015. Interrelationships Between Ki67, HER2/neu, p53, ER and PR Status and Their Associations with Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes. *Medicine*, Vol. 94, No. 32, pp. 1-6.
- Siregar KB, 2015. HER2 Overexpression in Relation to Breast Cancer Histopathological Grading: A Promising Prognostic and Predictive Biomarker for Breast Cancer. *Journal of Health, Medicine and Nursing*, Vol. 21, pp. 1-3.
- Skaland I, van Diest PJ, Janssen EAM, Gudlaugsson E, Baak JPA, 2008. Prognostic Differences of World Health Organization-assessed Mitotic Activity Index and Mitotic Impression by Quick Scanning in Invasive Ductal Breast Cancer Patients Younger than 55 Years. *Human Pathology*, Vol. 39, No. 4, pp. 584-90.
- Sledge GW, 2018. HER-2 Positive Breast Cancer. In (Bland KI, Copeland EM, Klimberg VS, Gradishar WJ, eds) *The Breast: Comprehensive Management of Benign and Malignant Diseases*, 5th ed. Philadelphia: Elsevier, pp. 763-8.
- Soliman NA, Yussif SM, 2016. Ki-67 as A Prognostic Marker According to Breast Cancer Molecular Subtype. *Cancer Biol Med*, Vol. 13, No. 4, pp. 496-504.
- Steinbeck RG, 2001. Pathologic Mitoses and Pathology of Mitosis in Tumorigenesis. *Eur J Histochem*, Vol. 45, No. 4, pp. 311-18.
- Strumfa I, Vanags A, Abolins A, Gardovskis J, 2012. Pathology of Breast Cancer: from Classic Concepts to Molecular Pathology and Pathogenesis. *Acta Chirurgica Latviensis*, Vol. 12, No. 1, pp. 59-66.
- Tan PH, Sahin AA, 2017. *Atlas of Differential Diagnosis in Breast Pathology, Atlas of Anatomic Pathology*. Springer Science+Business Media, pp. 417-35.
- Tinambunan A, Sulastri H, Julianita F, Bahar E, 2013. Hubungan Ekspresi Top2A dengan Karakteristik Histopatologi dan Status Reseptor Hormon pada Karsinoma Payudara Her-2 Positif. *Majalah Patologi Indonesia*, Vol. 22, No. 2, pp. 31-7.
- Tokiniwa H, Horiguchi J, Takata D *et al.*, 2012. Topoisomerase II Alpha Expression and The Ki-67 Labeling Index Correlate with Prognostic Factors in Estrogen Receptor-positive and Human Epidermal Growth

Factor Type-2-negative Breast Cancer. *Breast Cancer*, Vol. 19, No. 4, pp. 309-14.

Veta M, van Diest PJ, Jiwa M, Al-Janabi S, Pluim JPW, 2016. Mitosis Counting in Breast Cancer: Object Level Interobserver Agreement and Comparison to An Automatic Method. *PLoS ONE*, Vol. 11, No. 8, pp. 1-13.

Veta M, van Diest PJ, Willems SM *et al.*, 2015. Assessment of Algorithms for Mitosis Detection in Breast Cancer Histopathology Images. *Med Image Anal*, Vol. 20, No. 1, pp. 237-48.

Voudouri K, Berdiaki A, Tzardi M, Tzanakakis GN, Nikitovic D, 2015. Insulin-like Growth Factor and Epidermal Growth Factor Signaling in Breast Cancer Cell Growth: Focus on Endocrine Resistant Disease. *Analytical Cellular Pathology*, Hindawi Publishing Corporation, 975495, pp. 1-10. <http://dx.doi.org/10.1155/2015/975495>.

Viale G, 2012. The Current State of Breast Cancer Classification: Symposium Article. *Ann Oncol*, Vol. 23, Suppl 10, pp. x207-10.

Vu T, Claret FX, 2012. Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer. *Front Oncol*, Vol 2, No. 62, pp.1-6.

Waks AG, Winer EP, 2018. Chemotherapy and HER2-directed Therapy for Metastatic Breast Cancer. In (Bland KI, Copeland EM, Klimberg VS, Gradishar WJ, eds) *The Breast: Comprehensive Management of Benign and Malignant Diseases*, 5th ed. Philadelphia: Elsevier, pp. 885-906.

Wapnir IL, Tsai J, Aebi S, 2018. Locoregional Recurrence After Mastectomy. In (Bland KI, Copeland EM, Klimberg VS, Gradishar WJ, eds) *The Breast: Comprehensive Management of Benign and Malignant Diseases*, 5th ed. Philadelphia: Elsevier, pp. 808-13.

Widodo I, Dwianingsih EK, Triningsih E, Utoro T, Soeripto, 2014. Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes. *Asian Pac J Cancer Prev*, Vol. 15, No. 15, pp. 6109-13.

Wishart GC, Bajdik CD, Azzato EM *et al.*, 2011. A Population-based Validation of the Prognostic Model PREDICT for Early Breast Cancer. *Eur J Surg Oncol*, Vol. 37, No. 5, pp. 411-7.

Wu Y, Sahin AA, 2014. Molecular Classification and Testing of Breast Carcinoma. In (Hoda SA, Brogi E, Koerner FC, Rosen PP, eds) *Rosen's Breast Pathology*, 4th ed. Philadelphia: Wolters Kluwer, pp. 1337-49.

Yao D, Dong BQ, Xu XL, Xu WZ, Zou DH, 2017. TOP2A is An Independent Prognostic Factor in Patients with Operable Invasive Breast

Cancer: A Large-scale Study. *Int J Clin Exp Pathol*, Vol. 10, No. 3, pp. 3344-52.

Yip CH, 2009. Breast Cancer in Asia. *Methods Mol Biol*, No. 471, pp. 51-64.

Yip CH, Taib NAM, Mohamed I, 2006. Epidemiology of Breast Cancer in Malaysia. *Asian Pac J Cancer Prev*, Vol. 7, No. 3, pp. 369-74.

Youlten DR, Cramb SM, Yip CH, Baade PD, 2014. Incidence and Mortality of Female Breast Cancer in The Asia Pacific Region. *Cancer Biol Med*, Vol. 11, No. 2, pp. 101-15.

Zhong H, Chekmareva M, Deen M, May M, Deak S, Barnard N, 2014. Benign Reactive Lesion with Atypical Mitosis: New Example of An Old Story. *IJCRI*, Vol. 5, No. 3, pp. 235-39.

